In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months ...

Roche reveals new data on trontinemab and pTau217 testing, aiming to transform Alzheimer’s treatment and diagnosis.

Swiss pharma major Roche (ROG: SIX) has outlined ambitious plans to accelerate the development of trontinemab, its ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer’s ...

Roche Holdings AG said it will begin a late-stage trial to evaluate whether its experimental Alzheimer’s drug, trontinemab, ...

Roche is currently expanding trontinemab’s early-stage trial and hoping to get a couple hundred patients dosed before determining its next steps, Bonni said.

Roche has added another phase 3 trial in its programme for Alzheimer's disease candidate trontinemab and will now test the ...

Swiss pharmaceutical giant Roche is set to explore the potential of its experimental drug, Trontinemab, in delaying or ...

(Reuters) -Swiss drugmaker Roche Holding plans to investigate whether an experimental medicine can delay or prevent Alzheimer ...

Current health news covers Roche's Alzheimer's drug research, UnitedHealth's leadership hopes, Nordic Capital's ...

TORONTO -- An investigational antibody drug, designed to cross the blood-brain barrier (BBB) to eliminate amyloid-beta ...

A NEW “game-changing” drug could stop the progression of Alzheimer’s disease, early trials suggest. Scientists say the ...